Shenzhen, China - On November 23, 2022, the 86^th China International Medical Equipment Fair (“CMEF”) was held, and Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort^® MedBot^®”) made its debut with the flagship products. It showed the excellent style and strong strength of a leading domestic medical robot enterprise and joined the event with many experts from all over the country to concentrate and promote the rapid development of the industry together.

CMEF is known as the global industry vane and an "aircraft carrier" class medical industry event. Continuing the theme of "New Tech Smart Future", the event attracted over 4,000 brands and enterprises from 19 countries and regions, displaying medical devices and products in sub-sectors such as in vitro diagnosis, medical imaging, smart healthcare, rehabilitation and care for the elderly, home medical service, and intelligent manufacturing. The audience enjoyed a fascinating “global medical journey”.

MicroPort^® participated in the event with 114 products from 17 subsidiaries, and demonstrated its strategic layout of integrated total treatment solutions. MicroPort^® is an innovative high-end medical device group focusing on 12 business clusters, including cardiovascular and structural heart disease, electrophysiology and cardiac rhythm management systems, bone and soft tissue repair technology, aortic and peripheral vascular disease, cerebrovascular and neuromodulation science, surgical emergencies and robotics, endocrine management and assisted reproduction, urogynecology, digestive and respiratory diseases, ear, nose, mouth, eye and body cosmetic medicine, in vitro diagnosis and in vivo/vitro imaging, solid tumor treatment technology, insomnia, depression, and rehabilitation medicine.

It’s worth noting that MicroPort^® specially set up multiple online platforms such as “Cloud Streaming” and “Cloud Exhibition” to offer diversified interaction channels to users. Through coordinating 17 business fields, it provided a detailed introduction to 114 products and the MicroPort^® integrated total treatment solutions. The live stream attracted a large number of audiences, and many people watched the playback version after the broadcasting ended.

The leading cutting-edge medical devices demonstrated by MicroPort^® MedBot^® such as Toumai^® Laparoscopic Surgical Robot, Honghu Orthopedic Surgical Robot, DFVision^® 3D Electronic Laparoscopic, and R-ONE^®  Vascular Interventional Surgery Robot, attracted the attention of many audiences in Shenzhen, a city well known for innovation. These products were the eye catchers and triggered hot discussion on site.

Toumai^® Laparoscopic Surgical Robot is the first and the only four-arm laparoscopic surgical robot developed by a Chinese company and approved for marketing so far. Consisting of a surgeon console, a patient cart and a vision cart, it adopts client-server teleoperation technology to realize the surgical mode of doctors conducting the operation in a seated position away from the surgical console, thus reducing their burdens. Combined with the technological advantages of robotics, it allows for more minimally invasive, precise, stable and safe surgical operations, making it widely applicable in all kinds of surgeries, including urology, general surgery, gynecology, and thoracic surgery.

Honghu Orthopedic Surgical Robot was the first and the only Chinese-developed orthopedic surgery robot approved by the U.S. Food and Drug Administration. It can be used to assist total knee replacement by building a 3D knee joint model with its preoperative planning system based on the preoperative CT scanning data, and creating personalized prosthesis implantation surgical plans according to the physiological and anatomical features of the patient. It helps the surgeon quickly complete an osteotomy with the self-developed highly dexterous and lightweight robotic arm during surgery, allowing human-machine collaboration to complete precise osteotomy, and provides lower limb force line correction significantly better than traditional surgery after surgery, enhancing the precision and efficiency of surgery. The system may avoid injuries caused by medullary cavity positioning in traditional surgery, lessen complications, and help patients have a quicker recovery.

Consisting of high-resolution imaging objective and electron microscope structure, DFVision^® 3D Electronic Laparoscopic is the first 3D electronic laparoscope product to enter the “Green Path” in China. While preserving the full HD presentation of dual-channel images, it eliminates the cumbersome optical structure of the traditional laparoscope, and significantly reduces the weight of the body. The 3D imaging and rich colors vividly restore the surgical area, enhance the visual effect, and accurately present the anatomical layers of human organs, making it easier for the operator to operate and shortening the learning curve of the laparoscope. The three-dimensional and longitudinal surgical field provided by DFVision^® break through the limitations of traditional two-dimensional laparoscopic surgery, delivering excellent operation experience for both the surgeons in clinical practice and every audience that trials it at the event.

R-ONE^® Vascular Interventional Surgery Robot is an important innovative product that MicroPort^® MedBot^® develops in the field of vascular intervention, and has been awarded multiple patents: the only bionic technology for guidewire translation and rotation available in the world may perfectly reproduce an operator’s hand movement; the handle may be operated with a single hand, and complex operation such as dual guidewire and reverse translation may be completed with two hands; sub-millimetre stepwise and stable movements make the device more accurate. It has a movable one-piece large-angle radiation-shielding screen, and the doctors' workbench may be adjusted according to different catheterization rooms, allowing the surgeon to observe the patient's situation at any time and ensure patient safety; on-button release enables quick change with one person; switch to manual operation with one click may be realized in case of emergency; removal can be finished within 1 second after the surgery is completed. It is compatible with almost all PCI surgery devices without adding additional burden to the patient. With a minimalist design, it can minimize the cost of vascular interventional robotic surgery and reduce the risk of occupational exposure for doctors. Meanwhile, it helps make cardiac interventional treatment more accurate, safe, efficient and affordable, so that "good equipment" can serve more doctors and "good medicine" can serve more patients.

Innovation, Science and Technology Leading the Future MicroPort^® MedBot^® showed the strong strength of China's domestic surgical robots in this national medical industry stage, gaining attention and favor from all sectors. In the future, MicroPort^® MedBot^® will accelerate the promotion of medical technologies and products in markets by leveraging this strong industry platform, thus contributing to the construction of "Healthy China 2030" with richer and more intelligent medical solutions, and realizing the original intention of "Make Surgery Easier, Safer and Less Invasive".

The registered trademark of Honghu is named “SkyWalker” in abroad, which is in the process of application in the USA, and completed registration in the EU and other countries and regions.